PER 4.94% 8.5¢ percheron therapeutics limited

Ann: New data supports ATL1102s broader clinical potential, page-49

  1. 83 Posts.
    lightbulb Created with Sketch. 18
    One question with regard to partering,

    I am thinking for big pharma what would be the more reasonable choice for a partnering scenario

    1. partnering for DMD. It seems big pharma would take much less risk
    2. partnering for any new indication. This seems much more risky for any big pharma player
    3. Or does some company just buy in everything?

    At the current stage of the company does anyone have similar experiences?

    I hope any of the two outcomes will happen...
    Have a good day.
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
8.5¢
Change
0.004(4.94%)
Mkt cap ! $76.63M
Open High Low Value Volume
8.1¢ 8.5¢ 8.1¢ $46.54K 563.7K

Buyers (Bids)

No. Vol. Price($)
2 164616 8.1¢
 

Sellers (Offers)

Price($) Vol. No.
8.5¢ 100110 1
View Market Depth
Last trade - 15.55pm 28/06/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.